In fact, a retrospective study with 43 spondyloarthropathies treated with anti-TNF agents, noted that those receiving INX or ADB presented a lower rate of uveitis relapses than those treated with ETP (number of uveitis flares/100 patient-years before and during ETP treatment: 54.6 versus 58.5 [P = 0.92], number of uveitis flares/100 patient-years before and during INX or ADB treatment 50.6 versus 6.8 [P = 0.001]) [113]. Here, TNF is linked to uveitis.